Key Takeaways
- The FDA has missed the review deadline for Coya Therapeutics’ IND application, delaying a potential phase 2 trial for an ALS treatment.
- The FDA cited workload and resource constraints as reasons for the delay, rescheduling the decision for on or before August 29.
- Concerns have been raised about the FDA’s capacity, especially following significant job cuts under the previous administration.
FDA Delays Coya Therapeutics’ Drug Application Review
Coya Therapeutics is facing a setback as the FDA has missed the review deadline for its investigational new drug (IND) application, originally due on July 30. According to a filing with the Securities and Exchange Commission, the agency informed Coya on July 29 that it could not meet its initial goal due to a lack of resources and its ongoing workload.
The IND application is critical for Coya, as approval would permit the biotech to initiate a phase 2 trial for its investigational treatment for amyotrophic lateral sclerosis (ALS). The FDA has indicated that it will provide a decision by August 29. The delay complicates Coya’s path, extending the time required to potentially launch clinical trials for its lead product, COYA 302—a combination therapy designed to address ALS, dementia, Parkinson’s disease, and Alzheimer’s disease.
As of March 31, Coya reported having $35.5 million in cash, crucial for sustaining its operations. Small biotech firms like Coya often operate on tight financial resources, heavily reliant on regulatory approvals for further investment. The delay in FDA decision-making will likely put additional pressure on the company’s financial runway.
Concerns regarding the FDA’s efficiency and capacity to handle biotech applications have grown, particularly following significant workforce reductions. Over 3,500 employees were cut under the Trump administration, with assurances that these layoffs would not affect drug approval reviewers. However, subsequent missed deadlines for drug approvals have fueled skepticism regarding the agency’s operational capabilities.
In June, FDA Commissioner nominee Marty Makary claimed the agency was on track to meet approval targets, but just days later, KalVista Pharmaceuticals announced that its IND application would also be delayed due to the FDA’s constraints.
Coya Therapeutics’ situation reflects broader challenges faced by small biotech firms in navigating the regulatory landscape, particularly as the FDA continues to manage its resources amid ongoing scrutiny. The pressure to advance drug candidates is particularly acute in the fast-moving biotech sector, where timely approvals can significantly impact operational stability and project viability. As the industry awaits a decision by the FDA, the focus remains on how these delays will influence investor confidence and the future of innovative treatments for serious conditions like ALS.
The content above is a summary. For more details, see the source article.